Pfizer’s Xeljanz rheumatoid arthritis drug meets endpoints in ulcerative colitis trials
In the Octave Induction 1 and Octave Induction 2 studies, tofacitinib reduced symptoms of moderate to severe UC and induced remission of the disease. In one study, 18.5%
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.